These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28280887)

  • 1. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
    Schoemaker R; Wade JR; Stockis A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):727-733. PubMed ID: 28280887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration.
    Stockis A; Sargentini-Maier ML; Brodie MJ
    Epilepsy Res; 2016 Dec; 128():163-168. PubMed ID: 27842261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam.
    Schoemaker R; Krauwinkel W; Elshoff JP; Stockis A
    Epilepsy Res; 2024 May; 202():107332. PubMed ID: 38518434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
    Schoemaker R; Wade JR; Stockis A
    J Clin Pharmacol; 2016 Dec; 56(12):1591-1602. PubMed ID: 27146213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model for estimating individualized valproate clearance values in children.
    Botha JH; Gray AL; Miller R
    J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.
    Schoemaker R; Wade JR; D'Souza J; Stockis A
    Epilepsy Res; 2017 Nov; 137():95-100. PubMed ID: 28982069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro.
    Stockis A; Chanteux H; Rosa M; Rolan P
    Epilepsy Res; 2015 Jul; 113():19-27. PubMed ID: 25986188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
    Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
    J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Adjunctive Lacosamide in Pediatric Patients With Epilepsy.
    Winkler J; Schoemaker R; Stockis A
    J Clin Pharmacol; 2019 Apr; 59(4):541-547. PubMed ID: 30427550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.
    Toublanc N; Sargentini-Maier ML; Lacroix B; Jacqmin P; Stockis A
    Clin Pharmacokinet; 2008; 47(5):333-41. PubMed ID: 18399714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing valproate pharmacokinetics in children and adults.
    Jankovic SM; Milovanovic JR; Jankovic S
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):767-75. PubMed ID: 20979937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V
    Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients.
    Vučićević K; Jovanović M; Golubović B; Kovačević SV; Miljković B; Martinović Ž; Prostran M
    Eur J Clin Pharmacol; 2015 Feb; 71(2):183-90. PubMed ID: 25380628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy.
    Hagemann A; Klimpel D; Bien CG; Brandt C; May TW
    Epilepsia; 2020 May; 61(5):e43-e48. PubMed ID: 32304097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview.
    Yukawa E
    Drug Metabol Drug Interact; 2000; 16(2):86-98. PubMed ID: 10962642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial.
    Liu E; Dilley D; McDonough B; Stockis A; Daniels T
    Paediatr Drugs; 2019 Aug; 21(4):291-301. PubMed ID: 31250322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.
    Schoemaker R; Wade JR; Stockis A
    Clin Pharmacokinet; 2018 Jul; 57(7):843-854. PubMed ID: 28884437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.